Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q4 FY25 Earnings Presentation
37 slides from Gufic Biosciences's earnings presentation, May 30, 2025
Slide 1: Exchange filing cover letter
139/LG/SE/MAY/2025/GBSL May 30, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presentatio
Slide 2: Delivering Care & Cure - Investor Presentation May 2025
Delivering Care & Cure Investor Presentation May 2025
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This prese ntation does not constitute or form part of any offer or invitation
Slide 4: Q4 FY25 Business & Financial Highlights
Q4 FY25 Business & Financial Highlights
Slide 5: Q4 FY25 Business Highlights - Criticare Division
Q4 FY25 Business Highlights Criticare Division – Advancing Leadership in Hospital-Based Antimicrobials Focus continues towards deepening market penetration by realigning the field force around high-potential hospitals, leveraging in-person and hybrid engagements, and reinforcing scientific leadershi
Slide 6: Criticare pipeline and domestic business breakup
Q4 FY25 Business Highlights Criticare’s pipeline of products that address key therapeutic gaps and are complex to manufacture Domestic Business Breakup Drug Class Unique Advantages Complexity in Manufacturing Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual
Slide 7: Sparsh - Injectable solutions direct to hospitals
Q4 FY25 Business Highlights Sparsh – Offering comprehensive injectable solution beyond specialised antimicrobials direct to hospitals Quarter Summary ➢ Delivered a stable quarter while executing a soft launch of our new contrast-media portfolio, which have received encouraging initial uptake. ➢ Init
Slide 8: Ferticare Division - Assisted Reproductive Technology
Q4 FY25 Business Highlights Ferticare Division – Advancing Science-Driven Solutions in Assisted Reproductive Technology (ART) ➢ New Leadership, Renewed Focus Dr. Rajeev Agarwal—who successfully headed and built Gynae portfolio brands at BSV in his past stint—has taken charge of our Fertility Cluster
Slide 9: Aesthaderm - Injectable aesthetic solutions
Q4 FY25 Business Highlights Aesthaderm – offering a comprehensive portfolio of high-quality, scientifically-backed injectable solutions ➢ Proven Leadership: Our division is now helmed by Mr. Vijay Kumar, a seasoned industry veteran with a strong track record from his leadership roles at Galderma, br
Slide 10: Aesthaderm comparative study published in JCAS
Q4 FY25 Business Highlights Aesthaderm Published Comparative Study in renowned Journal JCAS Statistical signifcance reduction in crow’s feet wrinkles by STUNNOX® was observed & found non-inferior to international innovator brand with no adverse events. 9
Slide 11: NeuroCare: Therapeutic Botulinum Toxin in India
Q4 FY25 Business Highlights NeuroCare: Pioneering Therapeutic Botulinum Toxin in India Gufic's NeuroCare division is singularly focused on expanding the use of therapeutic botulinum toxin for neurological conditions in India and Nepal. Our strategy centers on building physician expertise, enhancing
Slide 12: Zenova Division (erstwhile Spark & Stellar)
Q4 FY25 Business Highlights Zenova Division (erstwhile Spark & Stellar): Formation of Zenova ▪ Consolidated Spark and Stellar into a single, specialty-focused division to eliminate overlap and streamline engagement ▪ Enhanced productivity via territory rationalization, reducing duplication and optim
Slide 13: Q3 FY25 Healthcare Division - Pain Management & Ayurveda
Q3 FY25 Business Highlights Healthcare Division – Advancing Pain Management & Ayurveda-Based Therapeutics The Healthcare division is focused on Ayurvedic and integrative therapies for musculoskeletal and joint disorders—most notably cervical spondylosis, chronic joint pain, osteoarthritis and gout—w
Slide 14: Q3 FY25 International Business
Q3 FY25 Business Highlights International Business ➢ Strategic Leadership Appointment: We are excited to announce the appointment of Dr. Rajasekar as President – International Business. With over two decades of global MNC experience, including instrumental roles in securing USFDA approvals, Dr. Raja
Slide 15: Indore Facility: Temporary Ramp-Up & Profitability Impact
Q4 FY25 Business Highlights Indore Facility: Temporary Ramp-Up & Profitability Impact What Changed (delay drivers): Mitigating Actions & Timeline: ➢ Media-fill & aseptic validations extended to meet evolving Audit & Qualification Milestones regulator expectations ➢ 16 customer audits: all major part
Slide 16: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical Developing SVX-3001 (humanized anti-CD40 agonist antibody) co-administered intratumorally with IL-2 to API Manufacturing: Our foray into peptides research amplify anti-tumour immune response wh
Slide 17: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 18: Profit & Loss Statement
Profit & Loss Statement Particulars (in Rs. Crore) Q4 FY 25 Q3 FY 25 Q4 FY 24 FY 25 FY 24 Total Revenue 205 207.8 195 819.8 806.7 EBITDA 27 35.8 35.1 138.6 148 EBITDA Margin % 13.17% 17.23% 18.00% 16.91% 18.35% Profit before Tax 10.8 26.2 27.1 94.4 115.7 PBT Margins % 5.27% 12.61% 13.90% 11.52% 14.3
Slide 19: Company Overview
Company Overview
Slide 20: About Gufic Biosciences - Business Structure
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 21: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 22: New Manufacturing Infrastructure
New Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Commercial Production Achieved Facility Carbapenems (Lyophilized / Dry Capability to cater to regulated Powder Inj / Oral Solids / Dual markets such as
Slide 23: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 24: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 25: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 26: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 27: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 28: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 29: Extensive Sales, Distribution and IT Infrastructure
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 30: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 31: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 32: Historical Financials
Historical Financials
Slide 33: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Income 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 138.6 148 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 16.83% 18.30% 19.79% 19.31% 17.85% 15.05% 15.77% Profit before Tax 94.4 115.7 106.7 126.8 57.7 30.1 40.2
Slide 34: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 601.3 532.5 347.8 269.1 173.4 129.3 75.3 Non-Current Liab
Slide 35: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 21.8 307.1 169.6 40.9 13.4 30.6 9.6 Righ
Slide 36: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment 43.7 34.1 29.6 23.2 30.8 24.7 13.4 or Financial Items Operating profit before working capital chang
Slide 37: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000